Clinical Practice Objectives
|
|
- Shannon Perry
- 6 years ago
- Views:
Transcription
1 STD Essentials for the Busy Clinician Susan S. Philip, MD, MPH Assistant Professor, Division of Infectious Diseases, UCSF Director, STD Prevention and Control Services San Francisco Department of Public Health Disclosures In the past 12 months, Dr. Philip has received research support from Abbott Diagnostics, Roche Diagnostics, Sera Care Life Sciences and Cepheid, Inc. The views expressed herein do not necessarily reflect the official policies of the City and County of San Francisco; nor does mention of the San Francisco Department of Public Health imply its endorsement. Clinical Practice Objectives Identify more CT and GC infections through screening Understand current issues in GC resistance Get more partners treated Review syphilis screening, clinical presentation and management THE source on STD management Diagnosis, treatment, prevention and vaccination Order hard copies Wall charts, pocket guides 1
2 Why Diagnose and Treat STDs? Majority of chlamydia, gonorrhea and early syphilis diagnosed outside of the STD Clinic 20 million STDs in US annually Cost: 16 billion (2010) Health consequences Pelvic Inflammatory Disease Ectopic pregnancy Infertility Neonatal HIV, herpes simplex virus (HSV) and congenital syphilis Increase risk of HIV 66% Men 34% 89% 11% Women CDC STD Surveillance 2008 Health Disparities Nationally there are populations who bear a disproportionate share of STDs Men who have sex with men (MSM) Adolescents African Americans Studies demonstrate that individual behaviors do not account for all the increase 1-3 Chlamydia Rates by Age and Sex, United States, 2010 Men Rate (per 100,000 population) Women 3,700 2,960 2,220 1, ,480 2,220 2,960 3,700 Age , Total 3, , , Ellen STD Laumann STD Oster AIDS
3 Chlamydia Rates by Race/Ethnicity, United States, Male STD Rates (per 100,000) San Francisco Rate (per 100,000 population) American Indians/Alaska Natives Asians/Pacific Islanders Blacks Hispanics Whites MSM Other Men Rate Ratio MSM Other Men Rate Ratio Chlamydia Gonorrhea Year Early Syphilis Guiding Principles in STD Management More than one infection is possible Full STD evaluation is warranted HIV assessment Single dose therapy preferable to maximize adherence Treatment of partners important Empiric treatment of contacts Expedited partner therapy Reinfection common Case 1 A 32 yo male patient presents for a routine visit. His past medical history is notable for hypercholesterolemia. He has sex with men, and reports having 5 sex partners over the last year. He usually asks his partners about their HIV-status and only has sex with HIVnegative men. 3
4 Case 1 Question 1 STD Screening What STD tests should you obtain today? 1. HIV Antibody test 2. Pharyngeal swab for gonorrhea (GC) and Chlamydia (CT) by nucleic acid amplification (NAAT) 3. Rectal swab for GC and CT by NAAT 4. Syphilis test 5. All of the above H I V A n t i b o d y t e s t 0% 0% P h a r y n g e a l s w a b f o r g o... R e c t a l s w a b f o r G C a n d C... 0% S y p h i l i s t e s t 0% A l l o f t h e a b o v e 100% Obtain a sexual history on all patients Five P s Partners Sex, numbers, concurrency Prevention of pregnancy Protection from STDs Practices Vaginal, anal and oral sex Past history of STDs STD Screening among MSM Perform at least annually: HIV serology Syphilis serology Rectal GC/CT NAAT in men who have had receptive anal intercourse in last year Pharyngeal GC/CT NAAT in men who have had receptive oral intercourse in last year Urine GC/CT NAAT in men who have had insertive anal intercourse in last year Additional screening and prevention recommendations for MSM Hepatitis B Screening (HBsAg) Vaccination against hepatitis A and B if previous infection or immunization cannot be documented Consider screening for hepatitis C Anal pap smears an area of ongoing research and debate 4
5 GC/CT NAAT testing for MSM: Which sites should I test? Proportion of asymptomatic rectal and urethral chlamydial and gonococcal infection among MSM San Francisco, 2003 Rectal Infections 14% 16% 86% 84% Urethral Infections Chlamydia n=316 42% Gonorrhea n=264 10% Asymptomatic Symptomatic 58% Kent, CK et al, Clin Infect Dis July 2005 Chlamydia n=315 90% Gonorrhea n=364 Urogenital and Extragenital NAAT Testing, MSM, San Francisco, % 80% 14.3% Case 1 (continued) You are able to send the tests to your local lab that has done validation studies to allow their use for clinical care. 60% 40% 20% 85.7% 91.4% Identified infections Missed infections The pharyngeal NAAT is positive for gonorrhea. The Chlamydia NAAT is negative at both the rectum and pharynx. 0% Urethral screening only 8.6% Rectal and pharyngeal screening only How would you manage this patient? 5
6 Case 1 Question 2 1. Prescribe a single dose of ciprofloxacin 500 mg and obtain a test of cure 2. Treat with a single intramuscular injection of ceftriaxone 250 mg 3. Treat with cefixime 400 mg orally x1 and azithromycin 1 g orally x1 4. Treat with a single intramuscular injection of ceftriaxone 250 mg and azithromycin 1 g orally x or 4 P r e s c r i b e a s i... 7% 7% T r e a t w i t h a s... T r e a t w i t h c e f... 0% T r e a t w i t h a s... 29% 57% 3 o r 4 Recommended Gonorrhea Treatment: Pharyngeal or Anogenital Ceftriaxone 250mg IM x 1 + Azithromycin 1g PO x 1 OR Doxycycline 100mg PO bid x 7 days This is dual treatment for GC add the azithromycin or doxycycline regardless of CT result Alternative Gonorrhea Tx: Anogenital only Cefixime 400mg PO x 1 + Azithromycin 1g PO x 1 OR Doxycycline 100mg PO bid x 7 days August 10, 2012 This is Dual treatment for GC add the azithromycin or doxycycline regardless of CT result Any non-ceftriaxone based regimen need NAAT Test of cure at 7 days! 6
7 Alternative Gonorrhea Tx Cephalosporin allergy Azithromycin 2g PO x 1 * Katz MMWR 2011 Use with Caution: decreased susceptibility has been documented in Hawaii, San Diego, San Francisco* Any non-ceftriaxone based regimen need NAAT Test of cure at 7 days! History of Antibiotics for GC Sulfa 50K units Penicillin PPNG 4800K units Tetracycline 3rd Gen Ceph Spectinomycin Cipro Penicillinase-Producing N. Gonorrhoeae (1970s s) Spread of Ciprofloxacin Resistance (1990s s) Courtesy P. Barry MD MPH 7
8 ? Spread of Cephalosporin Resistance (2000s) Trends in Cephalosporin susceptibility among N. gonorrhea Cefixime Ceftriaxone MMWR July 8, 2011 NEJM
9 Strain H041, identified in Japanese commercial sex worker, asymptomatic pharyngeal carrier High-level resistance to all cephalosporin-class antibiotics, penicillin G, levofloxacin Reduced susceptibility to azithromycin Susceptible to spectinomycin No secondary cases identified to date 9/133 (6.7%) of patients with cultureconfirmed GC had treatment failure Treatment failure associated with elevated cefixime MIC Allen VG et al. JAMA 2013; Groopman J New Yorker New guidelines for gonorrhea treatment What about Patients with Penicillin or Cephalosporin Allergies? Dual treatment may hinder development of antibiotic resistance Summary of changes: 1) Ceftriaxone IM preferred over oral cephalosporins 2) Ceftriaxone dose increased to 250 mg IM 3) Dual treatment for gonorrhea regardless of chlamydia test result Clarify that it is a true allergy If rash with PCN, generally ok to treat with ceftriaxone, as low rates of cross-reaction If severe allergy to PCN or cephalosporins, consider consulting your local DPH, can treat with azithromycin 2g PO x 1 Patient should be followed closely for resolution of symptoms (if present) and brought back for NAAT test of cure 9
10 Suspected GC Treatment Failure Syphilis Consider repeat infection: Ask patient about sexual activity since treatment and ensure partners were treated Re-test with a NAAT and GC culture If GC culture not available on-site, call your local or state public health for resources Re-treat with CTX 500 mg IM and Azithromycin 2 g PO Report to your local or state health department within 24 hours Obtain a test of cure Treponema pallidum Obligate human pathogen Visible by darkfield microscopy Cannot be readily cultured in vitro Primary & Secondary Syphilis, California, Number of Cases 2,250 2,000 1,750 1,500 1,250 1, MEN MSM WOMEN Year 10
11 Primary Syphilis Secondary syphilis Images courtesy of Joe Engelman City Clinic Secondary Syphilis Case 2 One of your new primary care patients is an HIVinfected woman. At her initial visit, you obtain baseline labs. The lab tells you that they have a new protocol for syphilis screening they are using treponemal EIA as the screening test Your patient s results: EIA positive, RPR negative. Now what? Images courtesy of Joe Engelman City Clinic 11
12 Case 2 Syphilis Screening Paradigm 1. Treat with one shot of Penicillin G 2. Treat with three shots of Penicillin G 3. Tell her you would like to schedule an LP to rule out neurosyphilis, prior to deciding about treatment course 4. Obtain another syphilis test 5. Do nothing further as this is unlikely active syphilis 16% 32% 5% 32% 16% Non-treponemal tests (i.e., RPR, VDRL) Non-specific to TP Quantitative Reactivity declines with time TRADITIONAL reflex to Treponemal tests (i.e., TPPA, FTA-Abs) Specific to TP Qualitative Reactivity persists over time T r e a t w i t h o n e... T r e a t w i t h t h r... T e l l h e r y o u w... O b t a i n a n o t h e r... D o n o t h i n g f u r... Treponemal EIA/CIA Tests Reduce time and labor required for screening If positive, need quantitative RPR/VDRL for confirmation and to guide clinical management Remain detectable for life, even after successful treatment Limited utility as a screening test in previously treated patients Reverse Sequence Syphilis Screening Test Result EIA- EIA+ /RPR+ EIA+/RPR-/TPPA+ Interpretation/ Comments Negative result, no further testing indicated. High negative predictive value > 98% Active syphilis vs. old, treated syphilis History, PHYSICAL EXAM, Quantitative RPR titer 1) Old, treated syphilis or 2) Old, untreated syphilis or 3) Early syphilis or 4) Prozone phenomenon; History and PE EIA+/RPR-/TPPA- Likely false positive; no treatment 12
13 Back to the patient You order a TPPA which comes back positive (EIA +, RPR-, TPPA+) You perform a thorough physical exam and do not detect any signs of syphilis The patient reports no prior history of syphilis and no known syphilis contacts in last year CD4 200, VL 60,000 Case 2 What now? 1. Treat with one shot of Penicillin G 2. Treat with three shots of Penicillin G 3. Tell her you would like to schedule an LP to rule out neurosyphilis, prior to deciding about treatment course 4. Obtain another syphilis test 5. Do nothing further as this is unlikely active syphilis T r e a t w i t h o n e... 22% T r e a t w i t h t h r... 52% T e l l h e r y o u w... 26% O b t a i n a n o t h e r... 0% D o n o t h i n g f u r... 0% Staging determines Treatment If you cannot ascertain that infection has happened in < 1 year, then must treat for late disease What can help pinpoint timing of infection? Signs or symptoms of primary or secondary Can recall those symptoms in past year Contact to a known case in past year Negative syphilis test in the past year In HIV-infected patients, consider getting syphilis test with every CD4 or VL, so approx every 3-6 months Syphilis Treatment Primary, Secondary & Early Latent: Benzathine penicillin G 2.4 million units IM in a single dose Late Latent and Unknown Duration: Benzathine Penicillin G 7.2 million units total, given as 3 doses of 2.4 million units each at 1 week intervals Neurosyphilis: Aqueous Crystalline Penicillin G million units IV daily administered as 3-4 million IV q 4 hr for d *** 2010 CDC STD Treatment Guidelines clearly state: No enhanced efficacy of additional doses of Benzathine PCN G, amoxicillin or other antibiotics even if HIV-infected 13
14 Syphilis When to LP? Clinical signs of neurosyphilis Cranial nerve dysfunction, meningitis, stroke, acute or chronic altered mental status, auditory or ophthalmic abnormalities Serologic treatment failure Evidence of active tertiary syphilis (e.g. aortitis and gumma) HIV positive and late latent syphilis or syphilis of unknown duration How to Manage Patients with Serologic Treatment Failure? Optimal approach unknown Treatment failure or reinfection? Slower decline in titers may be observed in HIV patients If lack of 4-fold decline in RPR titers, LP to r/o neurosyphilis: If CSF normal, then re-treat: BPG 2.4 MU qweek x 3 wks If 4-fold decline but still positive ( serofast ) No data to recommend additional treatment Case 3 A 22 year old female patient presents for a pre-travel visit (she s going to Cancun on her college spring break). She has no complaints. The EMR alerts you that her last Chlamydia test was 2 years ago, and there is a standing order in the office that the MA will obtain the test unless the patient opts out Case 3 Your lab is performing nucleic acid amplification testing (NAAT) for C. trachomatis. What is the best specimen to obtain? 1. Clinician collected cervical swab 2. Urine 3. Clinician or patient collected vaginal swab C l i n i c i a n c o l l... 37% 37% U r i n e 26% C l i n i c i a n o r p... 14
15 Chlamydia screening The United States Preventive Services Task Force (USPSTF) level A (highest) recommendation: C. trachomatis screening in sexually active females <25 Has been a managed care quality assurance (HEDIS) measure since 2000 in sexually active females NAAT Specimen types for the diagnosis of CT and GC in women Vaginal Swabs Sensitivity is equal or greater to cervical swabs Option for self-collection allows for further routinization of screening Less specimen processing required at clinical site than with urine Liquid cytology media ok for NAATs Case 3 (continued) This patient was positive for C. trachomatis at screening She was treated appropriately with Azithromycin 1g PO x 1, and given a prescription to take to her partner as expedited partner therapy (EPT) Rescheduled for repeat testing in 3 months Hobbs STD 2008, Chernesky STD
16 Patient Delivered Partner Therapy (PDPT) Meds or prescription given to patient to deliver to partner without prior medical evaluation. 3 RCTs demonstrate effectiveness of PDPT, rate of reinfection (GC> CT) Many states now allow clinicians to provide additional Rx for partners Treatment instructions, appropriate warnings and recommendations to seek personal medical evaluation should accompany PDPT. Patient Delivered Partner Therapy (PDPT) Current legal status of PDPT by jurisdiction: /std/ept Accessed 6/25/2013 Repeat Chlamydial Infection is Common Repeat Infection is Dangerous Reinfection (%) Months Follow-up Retesting Prevalence Typical Screening Prevalence Repeat CT infection leads to higher risk of complications: PID, ectopic pregnancy, infertility Most infections are asymptomatic Relative Risk st Infection 2nd Infection 3rd Infection Pelvic Inflammatory Disease Ectopic Pregnancy Hosenfeld C, et al. Sex Transm Dis Aug;36(8): Hillis SD, et al. (1997). Am J Obstet Gynecol 176(1 Pt 1):
17 Retesting Recommendations: Retest all women and men with CT or GC 3 months after treatment If client returns earlier than 3 months, consider retest If client does not return for retesting at 3 months, retest when possible CDC 2010 STD Tx Guidelines, Stephanie Cohen, MD, MPH Joe Engelman, MD California STD/HIV Training Center San Francisco City Clinic Susan.Philip@sfdph.org Stephanie.cohen@sfdph.org Thank You! 17
STD Essentials for the Busy Clinician. Stephanie E. Cohen, MD, MPH
STD Essentials for the Busy Clinician Stephanie E. Cohen, MD, MPH Assistant Professor, Division of Infectious Diseases, UCSF Medical Director, City Clinic San Francisco Department of Public Health Disclosures
More information5/1/2017. Sexually Transmitted Diseases Burning Questions
Sexually Transmitted Diseases Burning Questions Jeffrey D. Klausner, MD, MPH Professor of Medicine and Public Health University of California Los Angeles Los Angeles, California FORMATTED: 04-03-17 Financial
More informationDisclosures. STD Screening for Women. Chlamydia & Gonorrhea. I have no disclosures or conflicts of interest to report.
Disclosures Management of STIs: Challenges in Practice I have no disclosures or conflicts of interest to report. Alison O. Marshall, MSN, FNP-C Associate Professor of Practice & Director of the Family
More informationNothing to disclose.
Update on Diagnosis and Treatment Lisa Winston, MD University of California, San Francisco/ Zuckerberg San Francisco General Nothing to disclose. 1 This talk will be a little depressing Rising incidence
More information6/11/15. BACTERIAL STDs IN A POST- HIV WORLD. Learning Objectives. How big a problem are STIs in the U.S.?
BACTERIAL STDs IN A POST- HIV WORLD Tracey Graney, PhD, MT(ASCP) Monroe Community College Learning Objectives Describe the epidemiology and incidence of bacterial STDs in the U.S. Describe current detection
More informationOverview. Disclosures. Sexually Transmitted Diseases: What s New in the Guidelines and Beyond?
Sexually Transmitted Diseases: What s New in the Guidelines and Beyond? Susan S. Philip, MD, MPH Director, Disease Prevention and Control Branch Population Health Division San Francisco Department of Public
More informationRETURN OF THE CLAP: Emerging Issues in Gonorrhea Management and Antibiotic Resistance
RETURN OF THE CLAP: Emerging Issues in Gonorrhea Management and Antibiotic Resistance Ina Park, MD, MS University of California San Francisco California Prevention Training Center DISCLOSURE No Relevant
More informationAnswers to those burning questions -
Answers to those burning questions - Ann Avery MD Infectious Diseases Physician-MetroHealth Medical Center Assistant Professor- Case Western Reserve University SOM Medical Director -Cleveland Department
More informationKhalil G. Ghanem, MD, PhD Associate Professor of Medicine Johns Hopkins University School of Medicine. April 2, 2014
Khalil G. Ghanem, MD, PhD Associate Professor of Medicine Johns Hopkins University School of Medicine April 2, 2014 E-mail your questions for the presenter to: maphtc@jhsph.edu DISCLOSURES OFF- LABEL USES
More informationGenital Chlamydia and Gonorrhea Epidemiology, Diagnosis, and Management. William M. Geisler M.D., M.P.H. University of Alabama at Birmingham
Genital Chlamydia and Gonorrhea Epidemiology, Diagnosis, and Management William M. Geisler M.D., M.P.H. University of Alabama at Birmingham Chlamydia and Gonorrhea Current Epidemiology Chlamydia Epidemiology
More informationSTDs in HIV Clinical Care: New Guidelines on Treatment and Prevention
STDs in HIV Clinical Care: New Guidelines on Treatment and Prevention Palliative Care Conference Faculty Development Conference August 13, 2015 Steven C. Johnson M.D. Director, University of Colorado HIV/AIDS
More informationDidactic Series. STD Screening & Management: Syphilis. Christian B. Ramers, MD, MPH
Didactic Series STD Screening & Management: Syphilis Christian B. Ramers, MD, MPH Assistant Medical Director Family Health Centers of San Diego Ciaccio Memorial Clinic 3/26/15 ACCREDITATION STATEMENT:
More informationUpdate on Sexually Transmitted Infections Jeanne Marrazzo, MD, MPH
Update on Sexually Transmitted Infections Jeanne Marrazzo, MD, MPH Division of Infectious Diseases University of Alabama at Birmingham School of Medicine Birmingham, Alabama Outline Syphilis in all its
More informationSexually transmitted infections (in women)
Sexually transmitted infections (in women) Timothy Kremer, MD Assistant Professor, Department of Obstetrics and Gynecology University of North Texas Health Science Center Last official CDC guidelines:
More informationDisclosure Information Julie Stoltey, MD MPH
Courtesy CDC Public Health Image Library The New Yorker 2012 2016 Update on Testing, Treatment, and Gonorrhea Resistance Julie Stoltey, MD, MPH STD Control Branch-California Dept. of Public Health Assistant
More informationSexually Transmitted Diseases
Sexually Transmitted Diseases Ina Park, MD, MS California Prevention Training Center University of California San Francisco Dept of Family and Community Medicine Disclosures/Disclaimers No disclosures
More informationThe Great Imitator Revealed: Syphilis
The Great Imitator Revealed: Syphilis Jeffrey D. Klausner, MD, MPH Professor of Medicine and Public Health University of California Los Angeles David Geffen School of Medicine Los Angeles, California Learning
More informationEmerging Issues in STDs and Resistance
Emerging Issues in STDs and Resistance Toye H. Brewer, MD Asst. Professor of Clinical Medicine University of Miami School of Medicine Co-Director- Fogarty International Training Program Outline Syphilis-
More informationUse of Treponemal Immunoassays for Screening and Diagnosis of Syphilis
Use of Treponemal Immunoassays for Screening and Diagnosis of Syphilis Guidance for Medical Providers and Laboratories in California These guidelines were developed by the California Department of Public
More informationSTDs and Hepatitis C
STDs and Hepatitis C Catherine S. O Neal, MD Assistant Professor of Clinical Medicine, Infectious Diseases Louisiana State University Health Sciences Center March 3, 2018 Objectives Review patient risk
More information9/9/2015. Began to see a shift in 2012 Early syphilis cases more than doubled from year before
George Walton, MPH, CPH, MLS(ASCP) CM STD Program Manager Bureau of HIV, STD, and Hepatitis September 15, 2015 1 1) Discuss the changing epidemiology of syphilis in Iowa; 2) Explore key populations affected
More informationSexually transmitted infections (in women)
Sexually transmitted infections (in women) Timothy Kremer, MD Assistant Professor, Department of Obstetrics and Gynecology University of North Texas Health Science Center Last official CDC guidelines:
More informationSexually Transmitted Disease Treatment Tables
Sexually Transmitted Disease Treatment Tables Federal Bureau of Prisons Clinical Practice Guidelines June 2011 Clinical guidelines are made available to the public for informational purposes only. The
More informationThe (likely) New 2010 CDC STD Treatment Guidelines Guideline Development Process. Overview
The (likely) New 2010 CDC STD Treatment Guidelines http://www.cdc.gov/std/treatment Deborah Cohan, MD, MPH University of California, San Francisco San Francisco General Hospital cohand@obgyn.ucsf.edu I
More informationS403- Update on STIs for the Generalists
S403- Update on STIs for the Generalists Mobeen H. Rathore, MD Professor and Director University of Florida Center for HIV/AIDS Research Education and Service (UF CARES) Chief, Pediatric Infectious Diseases
More informationOverview. Disclosures. Sexually Transmitted Diseases: Key Clinical Information for 2017
Sexually Transmitted Diseases: Key Clinical Information for 2017 Susan S. Philip, MD, MPH Director, Disease Prevention and Control Branch Population Health Division San Francisco Department of Public Health
More informationSex, Sores, Science, and Surveillance: Syphilis in the 21 st Century (U046)
Sex, Sores, Science, and Surveillance: Syphilis in the 21 st Century (U046) Kenneth A. Katz, MD, MSc, MSCE Dermatologist, Kaiser Permanente, San Francisco, CA AAD Annual Meeting, Orlando, FL March 4, 2017
More informationSexually Transmitted Diseases. Summary of CDC Treatment Guidelines
DC 2015 Sexually Transmitted Diseases Summary of CDC Treatment Guidelines These summary guidelines reflect the June 2015 update to the 2010 CDC Guidelines for Treatment of Sexually Transmitted Diseases.
More informationSexually Transmitted Diseases:
Sexually Transmitted Diseases: Diagnosis and Management Department of Internal Medicine, Division of Infectious Diseases University of New Mexico A 21 year old woman comes to your clinic asking to be checked
More informationClinical Education Initiative TITLE: UPDATE ON MSM SEXUAL HEALTH. Speaker: Maureen Scahill, MS NP
Clinical Education Initiative Support@ceitraining.org TITLE: UPDATE ON MSM SEXUAL HEALTH Speaker: Maureen Scahill, MS NP 1/25/2017 2/10/2017 Update on MSM Sexual Health [video transcript] 00:00:08 - [Maureen]
More information2012 California Clinical Laboratory Survey: STD/HIV/Hepatitis Testing
2012 California Clinical Laboratory Survey: STD/HIV/Hepatitis Testing Joan M. Chow, MPH, DrPH Surveillance, Epidemiology, Assessment & Evaluation Section Sexually Transmitted Disease Control Branch Division
More informationTrends in Sexually Transmitted Infections (STIs) C. Junda Woo, MD, MPH, Medical Director San Antonio Metropolitan Health District June 3, 2017
Trends in Sexually Transmitted Infections (STIs) C. Junda Woo, MD, MPH, Medical Director San Antonio Metropolitan Health District June 3, 2017 1 Speaker Disclosure Dr. Woo has disclosed that she has no
More informationSex, Sores, Science, and Surveillance: Syphilis in the 21 st Century (U046)
Sex, Sores, Science, and Surveillance: Syphilis in the 21 st Century (U046) Kenneth A. Katz, MD, MSc, MSCE Dermatologist, Kaiser Permanente, San Francisco, CA AAD Annual Meeting, San Diego, CA February
More informationThe objectives of this presentation are; to increase awareness of the issue of antimicrobial resistant gonorrhea, and to inform primary care and
1 Antimicrobial resistant gonorrhea is an emerging public health threat that needs to be addressed. Neisseria gonorrhoeae is able to develop resistance to antimicrobials quickly. Effective antibiotic stewardship
More informationStephanie. STD Diagnosis and Treatment. STD Screening for Women. Physical Exam. Cervix with discharge from os
STD Diagnosis and Treatment Ina Park, MD, MS STD Control Branch, California Department of Public Health California STD/HIV Prevention Training Center Stephanie 23 year-old female presents for contraception,
More informationNovos desafios para controlar as infecções sexualmente transmissíveis [New Challenges in Managing Sexually Transmitted Infections]
Novos desafios para controlar as infecções sexualmente transmissíveis [New Challenges in Managing Sexually Transmitted Infections] Khalil Ghanem, MD, PhD Associate Professor of Medicine Directors, STD/HIV/TB
More informationBest Practices in STD Partner Management
Best Practices in STD Partner Management An Overview of Patient-Delivered Partner Therapy (PDPT) and Counseling for Partner Notification and Treatment Amber Eisenmann, MS Director of Learning Exchange
More informationChapter 11. Sexually Transmitted Diseases
Chapter 11. Sexually Transmitted Diseases General Guidelines Persons identified as having one sexually transmitted disease (STD) are at risk for others and should be screened as appropriate. Partners of
More informationSyphilis Update: New Presentations of an Old Disease
Syphilis Update: New Presentations of an Old Disease Bradley Stoner, MD, PhD Washington University in St. Louis Disclosure: Bradley Stoner, MD, PhD STDs in the United States Where do we stand right now?
More informationALASKA NATIVE MEDICAL CENTER SEXUALLY TRANSMITTED DISEASE SCREENING AND TREATMENT GUIDELINES
ALASKA NATIVE MEDICAL CENTER SEXUALLY TRANSMITTED DISEASE SCREENING AND TREATMENT GUIDELINES A. Screening Page Chlamydia and Gonorrhea 1 HIV 1 Syphilis 1 Genital Herpes 2 Hepatitis A 2 Hepatitis B 2 Hepatitis
More informationExtragenital Gonorrhea and Chlamydia among MSM
Extragenital Gonorrhea and Chlamydia among MSM Laura Quilter, MD Infectious Disease and STD PTC Fellow University of Washington Division of Allergy and Infectious Diseases 3/28/2016 uwptc@uw.edu uwptc.org
More informationPublic/Private Partnerships: Intervening in the Spread of Syphilis
Public/Private Partnerships: Intervening in the Spread of Diana Torres-Burgos MD, MPH Gerard Castaneda, BSN Alana Thomas, BS STD/HIV Update Conference Grand Rapids, MI 3/11/2014 Outline overview Stages
More informationUpdate on Sexually Transmitted Infections among Persons Living with HIV
Update on Sexually Transmitted Infections among Persons Living with HIV Stephen A. Berry, MD PhD Assistant Professor of Medicine Johns Hopkins University Division of Infectious Diseases Abbreviations and
More informationLisa Villarroel, MD MPH Medical Director, Division of Public Health Preparedness Arizona Department of Health Services.
Lisa Villarroel, MD MPH Medical Director, Division of Public Health Preparedness Arizona Department of Health Services Disclosures: None 1 PRIMARY Fitzgerald TJ, Cleveland P, Johnson RC et al: Scanning
More informationSTI Indicators by STI
STI Indicators by STI Table of Contents pg. 2 Sexual History pg. 3-4 Syphilis pg. 5-6 Gonorrhea pg. 7-9 Chlamydia pg. 10 HIV/PrEP 1 Sexual History Comprehensive Sexual History Elements Percentage of patients
More informationSTI 2016: Where We Need to Go
STI 2016: Where We Need to Go Gail Bolan, M.D. Director, Division of STD Prevention National Center for HIV/AIDS, Viral Hepatitis, STD and TB Prevention Centers for Disease Control and Prevention Sexually
More informationFamily Planning Title X Chlamydia Screening Quality Improvement Project
Family Planning Title X Chlamydia Screening Quality Improvement Project Illinois Department of Public Health STD Section Staff March 22, 2017 Objectives Discuss current STD trends and epidemiology of chlamydia
More informationWomen s Sexual Health: STI and HIV Screening. Barbara E. Wilgus, MSN, CRNP STD/HIV Prevention Training Center at Johns Hopkins
Women s Sexual Health: STI and HIV Screening Barbara E. Wilgus, MSN, CRNP STD/HIV Prevention Training Center at Johns Hopkins I have no disclosures! Review most recent rates of STIs and HIV across the
More informationSyphilis in the 21 st Century: Sex, Sores, Science, and Surveillance. Syphilis in Men
Syphilis in the 21 st Century: Sex, Sores, Science, and Surveillance Syphilis in Men Kenneth A. Katz, MD, MSc, MSCE Kaiser Permanente, San Francisco, CA AAD Annual Meeting Washington, D.C. March 2, 2019
More informationSyphilis Technical Instructions for Civil Surgeons
National Center for Emerging and Zoonotic Infectious Diseases Syphilis Technical Instructions for Civil Surgeons Joanna J. Regan, MD, MPH, FAAP Medical Officer Medical Assessment and Policy Team Immigrant,
More informationTrends in Reportable Sexually Transmitted Diseases in the United States, 2007
Trends in Reportable Sexually Transmitted Diseases in the United States, 2007 National Surveillance Data for Chlamydia, Gonorrhea, and Syphilis Sexually transmitted diseases (STDs) remain a major public
More informationLearning Objectives. STI Update. Case 1 6/1/2016
Learning Objectives STI Update June 16 th, 2016 Madhu Choudhary, MD. FIDSA Assoc. Prof of Medicine Albany Medical College Review screening recommendations for STI in different patient populations Describe
More informationReplaces: 04/13/17. / Formulated: 7/05 SYPHLIS
Effective Date: 81017 Replaces: 041317 Page 1 of 7 POLICY: The Texas Department of Criminal Justice (TDCJ) will identify, test, and manage all offenders with suspected or confirmed syphilis with a uniform
More informationSyphilis Treatment Protocol
STD, HIV, AND TB SECTION Syphilis Treatment Protocol CLINICAL GUIDANCE FOR PRIMARY AND SECONDARY SYPHILIS AND LATENT SYPHILIS www.lekarzol.com (4/2016) Page 1 of 8 Table of Contents Description... 3 Stages
More informationSexually Transmitted Diseases Treatment Guidelines, 2015
Morbidity and Mortality Weekly Report Recommendations and Reports / Vol. 64 / No. 3 June 5, 2015 Sexually Transmitted Diseases Treatment Guidelines, 2015 U.S. Department of Health and Human Services Centers
More informationCLINICAL MANAGEMENT OF STDS
CLINICAL MANAGEMENT OF STDS Diana Torres-Burgos MD, MPH NYC STD/HIV Prevention Training Center STD/HIV Update Conference Grand Rapids, MI 3/11/2014 Outline Essential components of STD care management Sexual
More informationManagement of Syphilis in Patients with HIV
Management of Syphilis in Patients with HIV Adult Clinical Guideline from the New York State Department of Health AIDS Institute www.hivguidelines.org Purpose of the Guideline Increase the numbers of NYS
More informationSyphilis: Screening (USPSFT) Syphilis: Screening. Sexually Transmitted Diseases. Family Medicine Board Review Course. Reference
Sexually Transmitted Diseases Family Medicine Board Review Course March 26, 2012 Ronald H. Goldschmidt, MD Reference Centers for Disease Control and Prevention Guidelines for Treatment of Sexually Transmitted
More informationClinical Education Initiative ADOLESCENTS AND STDS: CASE STUDIES. Tara Babu, MD
Clinical Education Initiative Support@ceitraining.org ADOLESCENTS AND STDS: CASE STUDIES Tara Babu, MD 2/16/2017 Adolescents and STDs: Case Studies [video transcript] 00:00:08 - Hello, my name is Tia Babu
More informationTrends in STDs: US Perspective. Michael Towns, M.D. WW Vice President, Medical Affairs BD Diagnostic Systems
Trends in STDs: US Perspective Michael Towns, M.D. WW Vice President, Medical Affairs BD Diagnostic Systems Outline Overview of STD Epidemiology and Current Situation in US Overview of Chlamydia infections
More informationManagement of Gonorrhea in Adolescents and Adults in the United States
SUPPLEMENT ARTICLE Management of Gonorrhea in Adolescents and Adults in the United States Sarah Kidd 1 and Kimberly A. Workowski 1,2 1 Division of STD Prevention, Centers for Disease Control and Prevention,
More informationClinical Guidelines Update (aka Know Your NAATs)
Clinical Guidelines Update (aka Know Your NAATs) WARNING: contains adult themes, sexual references and pictures that may be disturbing! Dr Heather Young Christchurch Sexual Health Centre heather.young@cdhb.health.nz
More informationWhat's the problem? - click where appropriate.
STI Tool v 1.9 @ 16/11/2017 What's the problem? - click where appropriate. Male problems: screening urethral symptoms proctitis in gay men lumps or swellings ulcers or sores skin rash and/or itch Female
More informationGuidelines for the Laboratory Detection of Chlamydia trachomatis, Neisseria gonorrhoeae and Treponema pallidum Testing
Guidelines for the Laboratory Detection of Chlamydia trachomatis, Neisseria gonorrhoeae and Treponema pallidum Testing Recommendations from the an expert consultation meeting held at CDC January 13-15,
More informationEdward W. Hook, III, M.D.
Challenging Cases Edward W. Hook III M.D. Professor and Director Division of Infectious Diseases University of Alabama at Birmingham And PI, Alabama/North Carolina STD PTC Edward W. Hook, III, M.D. Grant/Research
More informationSexually Transmitted Infections in the Adolescent Population. Abraham Lichtmacher MD FACOG Chief of Women s Services Lovelace Health System
Sexually Transmitted Infections in the Adolescent Population Abraham Lichtmacher MD FACOG Chief of Women s Services Lovelace Health System STI in the Adolescent High school students nationwide, 34.2% were
More informationSTD UPDATE 2017 FSACOFP CONVENTION
STD UPDATE 2017 FSACOFP CONVENTION L. Michael Waters, Jr, DO Adjunct Clinical Assistant Professor of Family Medicine LECOM-Bradenton Clinical Assistant Professor of Family Medicine PCOM- Georgia DISCLOSURES
More informationServices for GLBTQ Youth
Sexual Health Care Services for GLBTQ Youth Gale R Burstein, MD, MPH, FAAP, FSAHM Erie County Commissioner of Health Buffalo, NY Agenda Introduction Epidemiology Sexual health care services for YMSM Sexual
More informationWHAT DO U KNOW ABOUT STIS?
WHAT DO U KNOW ABOUT STIS? Rattiya Techakajornkeart MD. Bangrak STIs Cluster, Bureau of AIDS, TB and STIs, Department of Disease Control, MOPH, Thailand SEXUALLY TRANSMITTED INFECTIONS? STIs Infections
More information4/6/17 UNPRECEDENTED HIGH. Shelagh Larson, RNC, WHNP, NCMP
Shelagh Larson, RNC, WHNP, NCMP UNPRECEDENTED HIGH Total combined cases of chlamydia, gonorrhea, and syphilis reported in 2015 reached the highest number ever, according to the annualmore than 1.5 million
More informationScreening & Treating Chlamydia in Primary Care. Wednesday, September 21, 2016
Screening & Treating Chlamydia in Primary Care Wednesday, September 21, 2016 We Want To Hear From You! Type questions into the Questions Pane at any time during this presentation Patient-Centered Primary
More informationSyphilis Update. Dr. Bauer has no disclosures. STD Clinical Update San Diego California Prevention Training Center October 11, 2018
Heidi M. Bauer, MD MS MPH Chief, STD Control Branch, California Department of Public Health California STD/HIV Prevention Training Center San Diego Dr. Bauer has no disclosures 1 Learning Objectives 1.
More informationBest practices in chlamydia (CT) and gonorrhea (GC) screening in a changing healthcare environment:
Best practices in chlamydia (CT) and gonorrhea (GC) screening in a changing healthcare environment: Lessons from the Infertility Prevention Project (IPP) Goldenkranz Salomon S., Fine D., Curtiss J., Nakatsukasa-Ono
More informationClinical Cases from the STD Clinical Consultation Network
Clinical Cases from the STD Clinical Consultation Network Christine Johnston STD TCG April 24, 2017 Last Updated: uwptc@uw.edu uwptc.org 206-685-9850 STD Clinical Consultation Network (STDCCN) Developed
More informationSTD UPDATE Patrick Loose, Chief HIV, STD & Hepatitis Branch February 15, 2018
Patrick Loose, Chief HIV, STD & Hepatitis Branch February 15, 2018 MISSION Improve health outcomes in communities disproportionately impacted by HIV and STDs Collect, study and publish data Diagnose and
More informationSharon Adler M.D., M.P.H. California Prevention Training Center Assistant Clinical Professor UCSF FCM
Sharon Adler M.D., M.P.H. California Prevention Training Center Assistant Clinical Professor UCSF FCM Sharon Adler MD, MPH has no relevant financial relationships with an entity producing, marketing, re
More informationSTD Prevention Among Youth
STD Prevention Among Youth Jody Pierce Glover New Beginnings Emer S. Smith, MPH Maine Center for Disease Control & Prevention In Today s Talk... Maine Learning Results: Education Content Areas Health Behaviors
More informationSexually Transmitted Infections: New Tests, New Guidelines
Sexually Transmitted Infections: New Tests, New Guidelines Michael S. Policar, MD, MPH UCSF Ob, Gyn, and Reproductive Sciences No disclosures for this lecture Value of STI Screening and Testing Benefits
More informationTimby/Smith: Introductory Medical-Surgical Nursing, 9/e
Timby/Smith: Introductory Medical-Surgical Nursing, 9/e Chapter 62: Caring for Clients With Sexually Transmitted Diseases Slide 1 Epidemiology Introduction Study of the occurrence, distribution, and causes
More informationCategories of STI Screening and Testing Routine screening Population based risk factors Targeted screening Personal behavioral risk factors Contact te
Sexually Transmitted Infections: New Tests, New Guidelines Michael S. Policar, MD, MPH UCSF Ob, Gyn, and Reproductive Sciences No disclosures for this lecture Value of STI Screening and Testing Benefits
More informationSexually Transmitted Infection surveillance in Northern Ireland An analysis of data for the calendar year 2011
Sexually Transmitted Infection surveillance in Northern Ireland 2012 An analysis of data for the calendar year 2011 Contents Page Summary points. 3 Surveillance arrangements and sources of data.. 4 1:
More informationSTI Treatment Guidelines. Teodora Wi. Training Course in Sexual and Reproductive Health Research
Teodora Wi Geneva, 28 August 2017 STI Treatment Guidelines Teodora Wi Training Course in Sexual and Reproductive Health Research 2017 Twitter @HRPresearch 1 STI treatment guidelines Neisseria gonorrhoeae
More informationPodcast Transcript. Title: The STD Crisis in America: Where We Are and What Can Be Done Speaker Name: Bradley Stoner, MD, PhD Duration: 00:30:43
Podcast Transcript Title: The STD Crisis in America: Where We Are and What Can Be Done Speaker Name: Bradley Stoner, MD, PhD Duration: 00:30:43 NCTCFP: Welcome to this podcast sponsored by the National
More informationJanuary Dear Physician:
Richard F. Daines, M.D. Commissioner Wendy E. Saunders Executive Deputy Commissioner January 2009 Dear Physician: The purpose of this letter is to bring your attention to the significant increase in reported
More informationDisclosures. What s New in the 2015 CDC STD Treatment Guidelines. Outline. None
Disclosures None What s New in the 2015 CDC STD Treatment Guidelines Ina Park, MD, MS California STD/HIV Prevention Training Center UCSF Dept of Family and Community Medicine STD Control Branch California
More information10/29/2018 PROPHYLAXIS AND TREATMENT: CURBING THE ALARMING SPREAD OF SEXUALLY TRANSMITTED DISEASES DISCLOSURE OBJECTIVES FOR PHARMACISTS GOAL
DISCLOSURE PROPHYLAXIS AND TREATMENT: CURBING THE ALARMING SPREAD OF SEXUALLY TRANSMITTED DISEASES Dr. Feller does not have any actual or potential conflicts of interest to disclose and will not be discussing
More informationSyphilis among MSM: Clinical Care and Public Health Reporting
Massachusetts Department of Public Health Bureau of Infectious Disease and Laboratory Sciences Syphilis among MSM: Clinical Care and Public Health Reporting Kevin Ard, MD, MPH, Medical Director, National
More informationLymphogranuloma Venereum (LGV) Surveillance Project
Lymphogranuloma Venereum (LGV) Surveillance Project Lymphogranuloma venereum (LGV) is a systemic, sexually transmitted disease (STD) caused by a type of Chlamydia trachomatis (serovars L1, L2, L3) that
More informationSYPHILIS. The Great Pretender K. Amen Eguakun, MSN, APRN, AAHIVS
SYPHILIS The Great Pretender K. Amen Eguakun, MSN, APRN, AAHIVS Learning Objectives At the end of this presentation, the participants will be able to 1. Describe the epidemiology of syphilis in the United
More informationGAY MEN/MSM AND STD S IN NJ: TAKE BETTER CARE OF YOUR PATIENTS! STEVEN DUNAGAN SPECIAL PROJECTS COORDINATOR NJ DOH STD PROGRAM SEPTEMBER 27, 2016
GAY MEN/MSM AND STD S IN NJ: TAKE BETTER CARE OF YOUR PATIENTS! STEVEN DUNAGAN SPECIAL PROJECTS COORDINATOR NJ DOH STD PROGRAM SEPTEMBER 27, 2016 TOPICS FOR DISCUSSION What medical providers should know
More informationSay Ahhh!, STDs in Maine. Emer Smith, Maine CDC,
Say Ahhh!, STDs in Maine Emer Smith, Maine CDC, emer.smith@maine.gov Say AHHH! : STDs in Maine Emer S. Smith, MPH Maine Center for Disease Control & Prevention HIV, STD, & Viral Hepatitis Program April
More informationNeurosyphilis as an Emerging Feature in the HIV Setting. Christina M. Marra, MD University of Washington Seattle, WA, USA
Neurosyphilis as an Emerging Feature in the HIV Setting Christina M. Marra, MD University of Washington Seattle, WA, USA Syphilis in the Developing World Region 1995 1999 Sub-Saharan 3,530,000 3,828,000
More informationGonorrhea, Chlamydia, and Syphilis in Alaska
Department of Health and Social Services Division of Public Health Section of Epidemiology Karen Perdue, Commissioner Karen Pearson, Director John Middaugh, MD, Editor 361 C Street, Suite 54, P.O. Box
More informationChlamydia Trachomatis and Neisseria Gonorrhoeae. Khalil G. Ghanem, MD Johns Hopkins University
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike License. Your use of this material constitutes acceptance of that license and the conditions of use of materials on this
More informationSyphilis Update. roadmap
AND Nurse Practitioners!!! AND Physician Assistants!!! Oliver Bacon, MD, MPH Physician, SF City Clinic Disease Prevention and Control Branch Population Health Division roadmap 1. Syphilis: diagnosis and
More informationExtragenital Chlamydia and Gonorrhea. Angel Stachnik, MPH Sr. Epidemiologist Office of Epidemiology and Disease Surveillance
Extragenital Chlamydia and Gonorrhea Angel Stachnik, MPH Sr. Epidemiologist Office of Epidemiology and Disease Surveillance Rate of Chlamydia (CT) and Gonorrhea (GC), Clark County, 2012-2016 600 Rate per
More informationMedical Director, Community & Behavioral Health Clinics Department of Health and Human Services
Patrick F. Luedtke MD, MPH Senior Public Health Officer Medical Director, Community & Behavioral Health Clinics Department of Health and Human Services I have no relevant financial disclosures Review current
More informationNew Guidelines for Detection and Treatment of Sexually Transmitted Infections
UCSF Controversies in Women s health December 8, 2016 San Francisco, CA New Guidelines for Detection and Treatment of Sexually Transmitted Infections Disclosure I am a litigation consultant to a law firm
More informationMSM&TGpopulations. Management in. Sex. Sex. Outline. STIs/HIV. Sex. Sexual fluidity and HIV. Risk behavior. Recreational drugs
Outline MSM = (at least) 9 patients /day Management in MSM&TGpopulations OPASSPUTCHAROEN M.D. CHULALONGKORNUNIVERSITY BANGKOK, TH /HIV Recreational drugs ual fluidity and HIV Risk behavior AIDS Patient
More information10/29/2018 PROPHYLAXIS AND TREATMENT: CURBING THE ALARMING SPREAD OF SEXUALLY TRANSMITTED DISEASES DISCLOSURE GOAL
PROPHYLAXIS AND TREATMENT: CURBING THE ALARMING SPREAD OF SEXUALLY TRANSMITTED DISEASES Jade Feller, PharmD PGY-1 Pharmacy Resident Iowa City Veterans Affairs Health Care System November 13, 2018 DISCLOSURE
More information